Sterling Capital Management’s CervoMed CRVO Stock Holding History

Sterling Capital Management’s Portfolio CRVO Stock Details CRVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-6	Closed	-$55	–	3293
2025 Q1	$55	Hold	6	–	–	﹤0.01%	3174
2024 Q4	$14	Hold	6	–	–	﹤0.01%	3231
2024 Q3	$88	Buy	+6	New	+$93	﹤0.01%	3202
2018 Q4	–	Sell	-9	Closed	-$4K	–	864
2018 Q3	$4K	Buy	+9	New	+$4.19K	﹤0.01%	859

Other funds holding CRVO

AIC

AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

CFG

Citizens Financial Group Providence, Rhode Island $7.19B AUM 23.93% 1-Year Est. Return

AAS

Avantax Advisory Services Dallas, Texas $18.2B AUM 15.06% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Sterling Capital Management's CRVO Position: Q2 2025 in Review

Sterling Capital Management sold out of CervoMed (CRVO) in Q2 2025, closing a stake of 6 shares — an estimated $55 sold.

Sterling Capital Management first reported a position in CRVO in Q3 2018 and held it in 4 quarters. The position peaked at $4K in Q3 2018. 45 funds tracked by Wall St. Rank hold CRVO as of Q2 2025.

Sterling Capital Management reported no remaining CervoMed position as of Q2 2025 after selling out during the quarter.
Sterling Capital Management sold 6 CervoMed shares in Q2 2025, an estimated $55.
Sterling Capital Management first reported a position in CervoMed in Q3 2018 and held it in 4 quarters.
Sterling Capital Management's CervoMed position peaked at $4K in Q3 2018.
45 funds tracked by Wall St. Rank held CervoMed as of Q2 2025.

Based on Sterling Capital Management's 13F filing for Q2 2025, filed 6 Aug 2025.